Harrow 2025 Q3 Earnings Profitability Returns with 124.2% Net Income Surge

Harrow Inc. (HROW) reported mixed third-quarter results, . , reflecting Q3 momentum and Q4 optimism.

Revenue

, driven by robust performance in its core product sales. Product sales, net, , forming the bulk of revenue, . .

Earnings/Net Income

Harrow returned to profitability, , . , , underscoring the company’s operational efficiency and cost management.

Post-Earnings Price Action Review

Harrow’s stock price exhibited strong post-earnings momentum, . Month-to-date, , reflecting investor confidence in the company’s strategic initiatives and product launches. Despite the revenue miss, the profitability turnaround and updated guidance bolstered market sentiment.

CEO Commentary

, CEO & Chairman, emphasized Harrow’s growth trajectory, . He acknowledged challenges with TRIESENCE’s underperformance but expressed confidence in the Harrow Access for All program to reignite growth. Strategic priorities include scaling commercial infrastructure for upcoming product launches and addressing the California Board of Pharmacy dispute.

Guidance

, reflecting Q3 performance and Q4 expectations. , driven by VEVYE’s market share growth and IHEEZO’s unit demand. While a typical Q1 2026 seasonal decline is expected, Harrow remains optimistic about 2026 results, supported by improved coverage and product launches.

Additional News

Harrow’s recent acquisition of Melt Pharmaceuticals, a clinical-stage developer of , underscores its commitment to expanding its ophthalmic portfolio. The company also announced the launch of Harrow Access for All (HAFA), a program aimed at enhancing patient access to its medications. Additionally, an ongoing dispute with the California Board of Pharmacy over the Imprimus Rx license renewal poses a near-term risk, highlighting regulatory challenges in its operations.

Financial Health and Strategic Positioning

, reflecting efficient cost management. However, liquidity constraints, , remain areas of concern. The company’s focus on innovation, market access, and disciplined execution positions it to capitalize on its strong revenue growth and product pipeline, despite near-term regulatory and operational headwinds.